Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8766540 | 0.80 | — | — | |
| SCHEMBL1201511 | 0.76 | — | — | |
| SCHEMBL18415030 | 0.65 | — | — | |
| SCHEMBL6524180 | 0.65 | — | — | |
| SCHEMBL9527717 | 0.64 | GSK3A (0.46) | GSK3AGSK3B | |
| SCHEMBL943110 | 0.64 | GSK3A (0.46) | GSK3AGSK3B | |
| SCHEMBL7947539 | 0.63 | GSK3A (0.40) | GSK3AGSK3B | |
| SCHEMBL9529683 | 0.63 | GSK3A (0.40) | GSK3AGSK3B | |
| SCHEMBL225032 | 0.62 | GSK3A (0.43) | GSK3AGSK3B | |
| SCHEMBL7338785 | 0.62 | GSK3A (0.43) | GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884243-B2 | reacting 3,4-dihydo-1H-naphtalen-2-one oxime with acetic anhydride in tetrahydrofuran solvent using heterogenous catalyst ( Rh or Ir on Carbon support) in presence of hydrogen to perform hydrogenation/isomerization to form N-(3,4-Dihydro-naphthalen-2-yl)-acetamide | ZACH SYSTEM (FR) | 2011-02-08 | — | — | US | disclosed |
| EP-1716097-B1 | NEW PROCESS FOR THE SYNTHESIS OF ENEAMIDE DERIVATIVES | ZACH SYSTEM (FR) | 2010-10-13 | — | — | EP | disclosed |
| EP-1897868-A1 | N-(3H-inden-1-yl)-acetamide compounds | PPG-Sipsy (FR) | 2008-03-12 | — | — | EP | disclosed |
| US-20070129573-A1 | Process for the synthesis of eneamide derivatives | PPG-SIPSY (FR) | 2007-06-07 | — | — | US | disclosed |
| EP-1716097-A2 | NEW PROCESS FOR THE SYNTHESIS OF ENEAMIDE DERIVATIVES | PPG-Sipsy S.C.A. (FR) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005063687-A2 | NEW PROCESS FOR THE SYNTHESIS OF ENEAMIDE DERIVATIVES | PPG-SIPSY (FR) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129573-A1 | Process for the synthesis of eneamide derivatives | CBR3, CBR1, CYB5R3 | GSK3A 3735/4885GSK3B 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.